Evidence map›Paper›PMID 36230753›Full record

ArticleCancers2022

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.

Elena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, Jack O G Simpson, Zizhen Ming, Mal Irvine, Richard A Scolyer, Georgina V Long, Helen Rizos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elena ShklovskayaMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Bernadette PedersenMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Ashleigh StewartMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Jack O G SimpsonMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Zizhen MingMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Mal IrvineMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-8991-0013
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0001-8894-3545
Helen RizosMacquarie Medical School, Faculty of Medicine, Human and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0002-2094-9198
The University of Sydney · AUMacquarie University · AU

Funding

National Health and Medical Research Council 1128951, 1130423, 1104503 and 1093017
6 · The paper itself

Abstract

Immunotherapy has transformed the management of patients with advanced melanoma, with five-year overall survival rates reaching 52% for combination immunotherapies blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and programmed cell death-1 (PD1) immune axes. Yet, our understanding of local and systemic determinants of immunotherapy response and resistance is restrained by the paucity of preclinical models, particularly those for anti-PD1 monotherapy. We have therefore generated a novel murine model of melanoma by integrating key immunotherapy response biomarkers into the model development workflow. The resulting YUMM3.3

Indexed as

antigen presentationimmune checkpoint blockadeimmunological memoryinterferonmajor histocompatibility (MHC) class Imelanomamouse modelsT lymphocytes

Identifiers

PMID36230753
PMCPMC9564179
OpenAlexW4303614418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.